Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 4/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.56 |
| ▸ | PHLPP2 | Q6ZVD8 | 1/20 | 0.55 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.54 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.54 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.54 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.54 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.53 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30556174 | 0.85 | L3MBTL1 (0.76) | L3MBTL1LMNAALDH1A1KMT2ATDP1 | |
| SCHEMBL25009812 | 0.85 | L3MBTL1 (0.76) | L3MBTL1LMNAALDH1A1KMT2ATDP1 | |
| Nicametate SCHEMBL34040 | 0.85 | L3MBTL1 (0.68) | L3MBTL1LMNAALDH1A1KMT2ATDP1 | |
| Nicametate SCHEMBL5060940 | 0.85 | L3MBTL1 (0.68) | L3MBTL1LMNAALDH1A1KMT2ATDP1 | |
| SCHEMBL22983264 | 0.85 | RAB9A (0.60) | LMNAALDH1A1KMT2AGAAMAPT | |
| SCHEMBL382067 | 0.83 | L3MBTL1 (0.82) | L3MBTL1LMNAALDH1A1KMT2ATDP1 | |
| SCHEMBL11287619 | 0.83 | L3MBTL1 (0.68) | L3MBTL1LMNAALDH1A1KMT2ATDP1 | |
| SCHEMBL25009811 | 0.82 | L3MBTL1 (0.82) | L3MBTL1LMNAALDH1A1KMT2ATDP1 | |
| SCHEMBL21243071 | 0.82 | LMNA (0.82) | L3MBTL1LMNAALDH1A1KMT2ATDP1 | |
| Nicametate SCHEMBL28346401 | 0.82 | L3MBTL1 (0.63) | L3MBTL1LMNAALDH1A1KMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102232073-B | Ssao activity inhibitor | PROXIMAGEN LTD. (GB) | 2014-10-29 | — | — | CN | claimed |
| CN-103145704-A | 1,4-dihydro-1,8-nalidixic acid derivatives, their pharmaceutical composition and use of the pharmaceutical composition | JIANGSU SIMCERE PHARM CO LTD | 2013-06-12 | — | — | CN | claimed |
| CN-102232073-A | New compounds I | BIOVITRUM AB PUBL | 2011-11-02 | — | — | CN | claimed |
| US-20220390454-A1 | BIOMARKER PANEL TARGETED TO DISEASES DUE TO MULTIFACTORIAL ONTOLOGY OF GLYCOCALYX DISRUPTION | ARTEREZ, INC. (US) | 2022-12-08 | — | — | US | disclosed |
| WO-2021062298-A1 | BIOMARKER PANEL TARGETED TO DISEASES DUE TO MULTIFACTORIAL ONTOLOGY OF GLYCOCALYX DISRUPTION | ARTEREZ, INC. (US) | 2021-04-01 | — | — | WO | disclosed |
| US-20170267709-A1 | B-VITAMIN AND AMINO ACID CONJUGATES OFNICOTINOYL RIBOSIDES AND REDUCED NICOTINOYL RIBOSIDES, DERIVATIVES THEREOF, AND METHODS OF PREPARATION THEREOF | ChromaDex Inc. (US) | 2017-09-21 | — | — | US | disclosed |
| CN-106632317-A | 1,4-dihydro-naphthyridine derivative and pharmaceutical composition and application thereof | 江苏欧威医药有限公司 | 2017-05-10 | — | — | CN | disclosed |
| US-20170080006-A1 | METHODS AND COMPOSITIONS FOR REVERSING DISRUPTION OF THE GLYCOCALYX, INFLAMMATION, AND OXIDATIVE DAMAGE | KARDIATONOS, INC. (US) | 2017-03-23 | — | — | US | disclosed |
| CN-104203945-B | 1, 4-dihydro-naphthyridine derivatives, pharmaceutical compositions and uses thereof | 江苏欧威医药有限公司 | 2017-01-18 | — | — | CN | disclosed |
| CN-102232073-B | Ssao activity inhibitor | PROXIMAGEN LTD. (GB) | 2014-10-29 | — | — | CN | disclosed |
| CN-103145704-A | 1,4-dihydro-1,8-nalidixic acid derivatives, their pharmaceutical composition and use of the pharmaceutical composition | JIANGSU SIMCERE PHARM CO LTD | 2013-06-12 | — | — | CN | disclosed |
| CN-102232073-A | New compounds I | BIOVITRUM AB PUBL | 2011-11-02 | — | — | CN | disclosed |
| EP-0489581-A2 | Cosmetic composition | UNILEVER PLC (GB) | 1992-06-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170080006-A1 | METHODS AND COMPOSITIONS FOR REVERSING DISRUPTION OF THE GLYCOCALYX, INFLAMMATION, AND OXIDATIVE DAMAGE | MPO, VCAM1, NOX4 | L3MBTL1 4549/4885LMNA 176/4885ALDH1A1 2730/4885 |
| US-20220390454-A1 | BIOMARKER PANEL TARGETED TO DISEASES DUE TO MULTIFACTORIAL ONTOLOGY OF GLYCOCALYX DISRUPTION | SDCBP, LGALS2, SDC1 | L3MBTL1 3097/4885LMNA 869/4885ALDH1A1 1832/4885 |
| US-20170267709-A1 | B-VITAMIN AND AMINO ACID CONJUGATES OFNICOTINOYL RIBOSIDES AND REDUCED NICOTINOYL RIBOSIDES, DERIVATIVES THEREOF, AND METHODS OF PREPARATION THEREOF | NAMPT, NAPRT, NNMT | L3MBTL1 1938/4885LMNA 884/4885ALDH1A1 2260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.